RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure
A phase 2/3 trial of Disitamab vedotin, Gemcitabine, Capecitabine, Trastuzumab and Inetetamab in HER2-positive breast cancer and Breast cancer, run by Fudan University, not yet recruiting.
Overview
RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure is a phase 2/3 interventional study registered as NCT07366840 by Fudan University, with 268 participants planned, started 2026-01-16 and due to reach its primary completion in 2028-01-16. Interventions recorded: Disitamab Vedotin, Gemcitabine, Capecitabine, Trastuzumab, Inetetamab. Conditions recorded: HER2-positive Breast Cancer, Metastatic Breast Cancer.
Linked to the drug Inetetamab because the registry names it among its interventions and HER2-positive breast cancer and Breast cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Shares Inetetamab, Breast cancer (all types) and the tag pipeline.
- TrialInetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Shares Inetetamab, Breast cancer (all types) and the tag pipeline.
- TrialA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
Shares Capecitabine, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares Disitamab vedotin, Capecitabine, Trastuzumab and the tag pipeline.
- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares Capecitabine, Trastuzumab, Gemcitabine, HER2-positive breast cancer and the tag pipeline.
- TrialMARGetuximab Or Trastuzumab (MARGOT)
Shares Breast cancer (all types), Trastuzumab, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of DB-1310 in Advanced/Metastatic Solid Tumors
Shares Capecitabine, Trastuzumab and the tag pipeline.
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares Disitamab vedotin, HER2-positive breast cancer and the tag pipeline.